CD34 selected alloPBSCT and adoptive immunotherapy

Bone Marrow Transplantation

Volumn 25, Issue , 2000, Pages S2-S5

  Knauf, W ^a   Fietz, T ^a   Schrezenmeier, H ^a   Thiel, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AGVHD; CD34+ selection; Delayed add back of T cells

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CYCLOSPORIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANTIGENS, CD34; CYTOMEGALOVIRUS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; LYMPHOCYTE DEPLETION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; VIREMIA;

EID: 0033946919     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702342     Document Type: Article

References (12)

1. Prentice HG, Janossy G, Price-Jones L et al. Depletion of T lymphocytes in donor marrow prevents significant graft-ver sus-host disease in matched allogeneic leukemic marrow S5 transplant recipients. Lancet 1984; 1: 472-475.
2. Waldman HG, Hale G, Cividalli G et al. Elimination of graftversus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet 1984; 2: 483-486.
3. Ash RC, Casper JT, Chitambar CR et al. Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors. New Engl J Med 1990; 322: 485-494.
4. Patterson J, Prentic HG, Brenner MK et al. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986; 63: 221-230.
5. Apperley JF, Jones L, Hale G et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease, but may increase the risk of leukemia relapse. Bone Marrow Transplant 1986; 1: 53-66.
6. Goldman JM, Gale RB, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
7. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986; 68: 770-773.
8. Körbling M, Huh YQ, Durett A et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donorderived primitive hematopoietic progenitor cells (CD34 Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and GvHD. Blood 1995; 86: 2842-2848.
9. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
10. Urbano-Ispizua A, Rozman C, Martinez C et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantaion of CD34 selected cells from peripheral blood. Blood 1997; 89: 3967-3973.
11. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against CMV in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New Engl J Med 1995; 333: 1038-1044.
12. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.